276 related articles for article (PubMed ID: 28100839)
41. [Prospects and Challenges of Anti-VEGF Drug Treatment for Pathological Angiogenesis of the Retina].
Nakamura S; Hara H
Yakugaku Zasshi; 2021; 141(12):1307-1317. PubMed ID: 34853203
[TBL] [Abstract][Full Text] [Related]
42. Implication of the hypoxia response element of the Vegf promoter in mouse models of retinal and choroidal neovascularization, but not retinal vascular development.
Vinores SA; Xiao WH; Aslam S; Shen J; Oshima Y; Nambu H; Liu H; Carmeliet P; Campochiaro PA
J Cell Physiol; 2006 Mar; 206(3):749-58. PubMed ID: 16245301
[TBL] [Abstract][Full Text] [Related]
43. Ziv-aflibercept in macular disease.
Mansour AM; Al-Ghadban SI; Yunis MH; El-Sabban ME
Br J Ophthalmol; 2015 Aug; 99(8):1055-9. PubMed ID: 25677668
[TBL] [Abstract][Full Text] [Related]
44. Inhibition of Placenta Growth Factor Reduces Subretinal Mononuclear Phagocyte Accumulation in Choroidal Neovascularization.
Crespo-Garcia S; Corkhill C; Roubeix C; Davids AM; Kociok N; Strauss O; Joussen AM; Reichhart N
Invest Ophthalmol Vis Sci; 2017 Oct; 58(12):4997-5006. PubMed ID: 28979997
[TBL] [Abstract][Full Text] [Related]
45. Comprehensive Review of Ocular and Systemic Safety Events with Intravitreal Aflibercept Injection in Randomized Controlled Trials.
Kitchens JW; Do DV; Boyer DS; Thompson D; Gibson A; Saroj N; Vitti R; Berliner AJ; Kaiser PK
Ophthalmology; 2016 Jul; 123(7):1511-20. PubMed ID: 27084563
[TBL] [Abstract][Full Text] [Related]
46. Responses of Types 1 and 2 Neovascularization in Age-Related Macular Degeneration to Anti-Vascular Endothelial Growth Factor Treatment: Optical Coherence Tomography Angiography Analysis.
Kim JM; Cho HJ; Kim Y; Jung SH; Lee DW; Kim JW
Semin Ophthalmol; 2019; 34(3):168-176. PubMed ID: 31132283
[No Abstract] [Full Text] [Related]
47. Twelve-month safety of intravitreal injections of bevacizumab (Avastin): results of the Pan-American Collaborative Retina Study Group (PACORES).
Wu L; Martínez-Castellanos MA; Quiroz-Mercado H; Arevalo JF; Berrocal MH; Farah ME; Maia M; Roca JA; Rodriguez FJ;
Graefes Arch Clin Exp Ophthalmol; 2008 Jan; 246(1):81-7. PubMed ID: 17674014
[TBL] [Abstract][Full Text] [Related]
48. Characteristics and Outcomes of Full-thickness Macular Hole Repair in Patients Receiving Anti-VEGF Injections for Neovascular Age-related Macular Degeneration.
Ringeisen AL; Parke DW; Dev S
Int Ophthalmol Clin; 2019; 59(1):127-135. PubMed ID: 30585922
[No Abstract] [Full Text] [Related]
49. A potential therapeutic strategy for inhibition of ocular neovascularization with a new endogenous protein: rhEDI-8t.
Zhang L; Shen X; Lu Q; Zhou Q; Gu J; Gan R; Zhang H; Sun X; Xie B
Graefes Arch Clin Exp Ophthalmol; 2012 May; 250(5):731-9. PubMed ID: 21881847
[TBL] [Abstract][Full Text] [Related]
50. Aflibercept for the treatment of neovascular age-related macular degeneration.
Verner-Cole EA; Davis SJ; Lauer AK
Drugs Today (Barc); 2012 May; 48(5):317-29. PubMed ID: 22645720
[TBL] [Abstract][Full Text] [Related]
51. HL-217, a new topical anti-angiogenic agent, inhibits retinal vascular leakage and pathogenic subretinal neovascularization in Vldlr⁻/⁻ mice.
Kim J; Kim CS; Jo K; Cho YS; Kim HG; Lee GH; Lee YM; Sohn E; Kim JS
Biochem Biophys Res Commun; 2015 Jan; 456(1):53-8. PubMed ID: 25446077
[TBL] [Abstract][Full Text] [Related]
52. Aflibercept Action in a Rabbit Model of Chronic Retinal Neovascularization: Reversible Inhibition of Pathologic Leakage With Dose-Dependent Duration.
Cao J; MacPherson TC; Iglesias BV; Liu Y; Tirko N; Yancopoulos GD; Wiegand SJ; Romano C
Invest Ophthalmol Vis Sci; 2018 Feb; 59(2):1033-1044. PubMed ID: 29450547
[TBL] [Abstract][Full Text] [Related]
53. Antiangiogenic therapy for ischemic retinopathies.
Al-Latayfeh M; Silva PS; Sun JK; Aiello LP
Cold Spring Harb Perspect Med; 2012 Jun; 2(6):a006411. PubMed ID: 22675660
[TBL] [Abstract][Full Text] [Related]
54. [PPAR gamma: a novel pharmacological target against retinal and choroidal neovascularization].
Bonne C
J Fr Ophtalmol; 2005 Mar; 28(3):326-30. PubMed ID: 15883500
[TBL] [Abstract][Full Text] [Related]
55. VEGF-binding aptides and the inhibition of choroidal and retinal neovascularization.
Jo DH; Kim S; Kim D; Kim JH; Jon S; Kim JH
Biomaterials; 2014 Mar; 35(9):3052-9. PubMed ID: 24388818
[TBL] [Abstract][Full Text] [Related]
56. [Review and expert opinion in age related macular degeneration. Focus on the pathophysiology, angiogenesis and pharmacological and clinical data].
Weber M; Sennlaub F; Souied E; Cohen SY; Béhar-Cohen F; Milano G; Tadayoni R
J Fr Ophtalmol; 2014 Sep; 37(7):566-79. PubMed ID: 25190312
[TBL] [Abstract][Full Text] [Related]
57. INCIDENCE AND LONG-TERM VISUAL ACUITY OUTCOMES OF RETINAL PIGMENT EPITHELIUM TEARS AFTER INTRAVITREAL ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR TREATMENT OF NEOVASCULAR AGE-RELATED MACULAR DEGENERATION.
Vazquez-Alfageme C; Nicholson L; Hamilton RD; Patel PJ
Retina; 2019 Apr; 39(4):664-669. PubMed ID: 29324593
[TBL] [Abstract][Full Text] [Related]
58. Pathogenic role and therapeutic potential of pleiotrophin in mouse models of ocular vascular disease.
Wang W; LeBlanc ME; Chen X; Chen P; Ji Y; Brewer M; Tian H; Spring SR; Webster KA; Li W
Angiogenesis; 2017 Nov; 20(4):479-492. PubMed ID: 28447229
[TBL] [Abstract][Full Text] [Related]
59. Aflibercept: A review of its effect on the treatment of exudative age-related macular degeneration.
Papadopoulos Z
Eur J Ophthalmol; 2019 Jul; 29(4):368-378. PubMed ID: 30813810
[TBL] [Abstract][Full Text] [Related]
60. [New perspectives in the approach to diabetic macular edema. Aflibercept therapy].
Ruiz-Moreno JM
Arch Soc Esp Oftalmol; 2015 Mar; 90 Suppl 1():24-8. PubMed ID: 25925048
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
